TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM
TAU-2014-1: Phase I Trial of Mibefradil Dihydrochloride With Hypofractionated Re-Irradiation Therapy in Treating Patients With Recurrent Glioblastoma Multiforme (GBM)
Sponsor: Cavion, Inc.
This PHASE1 trial investigates Glioblastoma Multiforme (GBM) and is currently completed. Cavion, Inc. leads this study, which shows 11 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE1
-
Aug 2019 — Oct 2019 [monthly]
Completed PHASE1
▶ Show 6 earlier versions
-
May 2019 — Aug 2019 [monthly]
Completed PHASE1
-
Jun 2018 — May 2019 [monthly]
Completed PHASE1
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE1
-
Apr 2017 — Mar 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Feb 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE1
Status: Unknown Status → Active Not Recruiting
-
Jan 2017 — Feb 2017 [monthly]
Unknown Status PHASE1
First recorded
Aug 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cavion, Inc.
- Yale University
For direct contact, visit the study record on ClinicalTrials.gov .